KROS — Keros Therapeutics Inc

Keros Therapeutics Inc (KROS) is a biotechnology company listed on NASDAQ. It is led by Jasbir S. Seehra Ph.D., based in 1050 Waltham Street, Lexington, MA, United States, 02421, with about 87 employees. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Latest reported KROS revenue for 2025-09-30 was $14.1M. Net income was -$7.3M. Revenue was down 22.3% from 2025-06-30 to 2025-09-30. KROS currently screens at market cap $208.8M.

Use this KROS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KROS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KROS SEC filings page. Lician reads the product cache first so this HTML stays unique to Keros Therapeutics Inc even when a live quote feed is slow.